CS 2009
Alternative Names: CS-2009Latest Information Update: 17 Sep 2024
Price :
$50 *
At a glance
- Originator CStone Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours